Naver Stock Jumps on NVIDIA Partnership to Build South Korea’s AI Infrastructure 
Gold Prices Slide Nearly 2% Ahead of Key U.S. Inflation Data and Rising Middle East Tensions 
BHP Port Hedland Workers Back Strike Action Amid Pay Dispute 
Trump Signals Opposition to USMCA Renewal as U.S. Reviews Trade Relations with Canada and Mexico 
Apple Unveils Enhanced Apple Intelligence and Next-Generation Siri at WWDC 2026 
ECB Set to Raise Interest Rates as Energy Shock Fuels Eurozone Inflation Concerns 
OpenAI Files Confidential IPO Draft as AI Giants Race Toward Public Markets 
Oil Prices Surge Above $93 as Trump Escalates Iran Pressure and Strait of Hormuz Tensions Deepen 
Nvidia Expands South Korea AI Partnerships to Strengthen Data Center and Memory Chip Supply 
BOJ Rate Hike Expectations Rise as Weak Yen and Strong U.S. Jobs Data Increase Pressure 
US Dollar Slips Ahead of Key Inflation Data as Middle East Tensions Weigh on Markets 
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy 
South Korea Q1 GDP Growth Revised Higher as AI-Driven Exports Boost Economic Outlook 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Oracle Stock Falls Despite Earnings Beat as Company Plans $40 Billion Financing for FY2027 
Kremlin Says New EU Sanctions Won’t Hurt Russian Banks 
Qualcomm Stock Gains After Jensen Huang Endorsement 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
